Pulse Biosciences

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pulse Biosciences pivots to cardiac tech, eyes FDA device market

Pulse Biosciences reported financials, highlighted cardiac ablation technology, and pivoted towards an FDA-approved device for cellular repair, showcasing adaptability and strategic focus.
The company faces challenges in transitioning focus areas and managing financial projections but has strengths in innovation, market potential, and strategic autonomy.
Opportunities lie in licensing breakthrough technologies, commercial partnerships, regulatory milestones, and market disruption, positioning Pulse Biosciences for growth and success.
Overall, Pulse Biosciences' strategic shifts, financial prudence, and focus on innovation present a promising outlook for sustainable growth and market expansion.

Pulse Biosciences advances cardiac ablation tech with strong financials

Pulse Biosciences made notable progress in Q1 2023, showcasing financial improvements, key leadership additions, and advancements in developing innovative cardiac ablation technologies.
While facing challenges in clinical validation and regulatory processes, the company's strategic roadmap and focus on nsPFA technology position them well for future growth and success.
With a strong financial position, experienced leadership, and a clear vision for product development, Pulse Biosciences is poised to capitalize on the market opportunities in cardiac ablation.

Pulse Biosciences advances nsPFA technology in cardiac applications, boosts finances

Pulse Biosciences demonstrated strong progress in nsPFA technology for cardiac applications and showcased financial improvements.
While facing questions about study expansions and project exits, the company remains confident in its market position.
Opportunities lie in expanding nsPFA applications, leveraging positive feedback, and exploring strategic partnerships for growth.

Pulse Biosciences advances CellFX technology, reduces costs, eyes growth opportunities

Pulse Biosciences demonstrated strong performance in technology advancement, cost management, and stakeholder engagement, positioning the company for growth.
Despite challenges related to patent concerns, the company's focus on innovation, safety, and partnerships presents opportunities for expansion and market leadership.
With a solid financial position, strategic development goals, and a commitment to excellence, Pulse Biosciences is poised for continued success in the medical technology sector.

Pulse Biosciences advances innovative surgical technology with promising FDA clearances

Pulse Biosciences is optimistic about the future impact of its energy technology on surgery and emphasizes the importance of strong support structures for successful product launches.

Pulse Biosciences excels in Q2, poised for transformative medical advancements

Pulse Biosciences' Q2 2024 performance reflects progress, financial strength, and strategic focus on pivotal clinical trials.
While facing challenges such as increased costs and operational complexities, the company is well-positioned to leverage opportunities in transformative medical technologies.
With a solid financial foundation, strong leadership, and innovative products, Pulse Biosciences is poised for continued growth and market success.
Navigating regulatory hurdles and market competition will be key as the company advances its nano-PFA technology in medical treatments.

Pulse Biosciences reports Q3 loss, strengthens balance sheet for growth

Pulse Biosciences' Q3 2024 earnings call highlighted progress in medical applications, a strengthened balance sheet, and a focus on pivotal clinical studies in 2025.
While facing challenges with increased expenses and net loss, the company's innovative technology and strategic fundraising efforts position it for future growth.
Opportunities lie in advancing clinical studies, expanding product applications, and solidifying its presence in the healthcare market through strategic partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about December 27, 2024, to redeem the first tranche of common stock warrants, redeemable by the Company if the Company's stock trading price exceeds $16.50 for twenty consecutive trading days, that were issued as part of its.

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced that, on December 18, 2024, the Company's Co-Chairman and majority shareholder, Robert W. Duggan, exercised all of the warrants he acquired in the Company's 2024 rights offering, corresponding to $58.4 million totaling to 5,306,156 shares of Co.

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a new publication in the Journal of Thoracic and Cardiovascular Surgery. This preclinical study demonstrates the advantages of the nano-PFA Cardiac Surgical System over radiofrequency technology for the ablation of cardiac tissue. The study was designed to demonstrate the safety and efficacy of a new nan.

Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation for the treatment of benign thyroid nodules. Dr. Stefano Spiezia presented these excellent results today at the 2024 American Thyroid Association Annual Meeting. The preliminary data demonstrate.

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations Burke Barrett - President & Chief Executive Officer Mike Koffler - Vice President, Finance Conference Call Participants Operator Greetings, and welcome to the Pulse Biosciences' Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA or nano-PFA) technology, today announced business updates and financial results for the third quarter ended September 30, 2024. Recent Business Highlights Soft Tissue Ablation Placed nsPFA Percutaneous Electrode Systems with seven sites in the U.S. as part of a pilot program for clinical assessment with com.

Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D., who altogether will continue to support the development and clinical efforts for the Pulse Bi.

Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-877-407-0752 for domestic cal.

Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024

Pulse Biosciences (NASDAQ: PLSE ) just reported results for the second quarter of 2024. Pulse Biosciences reported earnings per share of -20 cents.

PLSE Stock Earnings: Pulse Biosciences Reported Results for Q2 2024

Pulse Biosciences Inc. (NASDAQ:PLSE ) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Philip Taylor - Investor Relations Burke Barrett - President & CEO Michael Koffler - VP of Finance Conference Call Participants Anthony Petrone - Mizuho Group Operator Greetings, and welcome to the Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA) technology, today announced business updates and preliminary financial results for the second quarter ended June 30, 2024. Recent Business Highlights Soft Tissue Ablation Completed the first procedure with the Percutaneous Electrode System in the United States following U.S. FDA 510(k) clearance for the.

Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed Co-Chairman of the Board alongside Co-Chairman Robert W. Duggan, serving as an independent director. “We are thrilled to have Paul join the Pulse Biosciences Board. His track reco.

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced treatment of the first two patients in the first-in-human feasibility study using its novel Cardiac Surgery System for the ablation of cardiac tissue for the treatment of atrial fibrillation. Dr. Bart Van Putte, Cardiothoracic Surgeon at St. Antonius Hospital, used the Company'.

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced plans to participate in two upcoming investor conferences. 9th Annual Needham MedTech & Diagnostics 1x1 Conference, virtual participation. Management will host 1x1 meetings on Tuesday, August 13, 2024. There will be no formal presentation. Canaccord Genuity Annual Growth Co.

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Pulse Biosciences, Inc. (NASDAQ: PLSE) on behalf of the company's shareholders. The investigation seeks to determine whether Pulse Bioscience's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Pulse Biosciences, Inc. (NASDAQ: PLSE)

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the second quarter 2024 after market close on Monday, August 12, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic caller.

Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that it has received the Breakthrough Device Designation from the U.S. FDA for the Company's Cardiac Surgery System for the ablation of cardiac tissue for the treatment of atrial fibrillation (AF). Pulse Biosciences' Cardiac Surgery System with Surgical Clamp is designed to pro.

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, announced today the closing of its rights offering and the final results thereof. The Company received basic subscriptions and over-subscriptions in excess of $83 million, equal to approximately 138% of the $60 million gross proceeds limit in the rights offering, and subscrip.

Pulse Biosciences, Inc. Announces the Closing of its Rights Offering

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, announced today the preliminary results of its rights offering, which expired at 5:00 p.m., Eastern Time, on June 26, 2024 (the “Expiration Date”). In accordance with the pricing structure described in the prospectus supplement relating to the rights offering, the final subsc.

Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that it has commenced its previously announced rights offering of up to $60,000,000 of units (the “Units,” and each, a “Unit”) at the Initial Price (as defined below). The subscription rights will expire and have no value if they are not exercised prior to 5:0.

Pulse Biosciences, Inc. Announces Commencement of Rights Offering

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse” or the “Company”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that the Company's Board of Directors has determined a new record date for the Company's previously announced rights offering (the “Rights Offering”), which will be available to all holders of record of the Company's common stock, par value $0.001 per share (the “Common S.

Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced CellFX nsPFA technology will be featured in multiple presentations at the upcoming Heart Rhythm Society (HRS) 2024 Annual Meeting in Boston, MA from May 16-19. “We look forward to our proprietary CellFX nsPFA technology being highlighted in six total presentations and abstracts, and in a live case.

Pulse Biosciences' CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology (“Pulse”), today announced enhancements to its executive leadership team to support its next pivotal phase of growth. Proven atrial fibrillation medical technology leader Burke T. Barrett has been appointed President and Chief Executive Officer effective immediately. Concurrently, the Company announced the appointm.

Pulse Biosciences Enhances Executive Leadership Team

Pulse Biosciences Inc (NASDAQ:PLSE ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Philip Taylor - Principal, Gilmartin Group LLC Kevin Danahy - President & CEO Michael Koffler - VP, Finance Mitchell Levinson - Chief Strategy Officer Darrin Uecker - CTO & Director Robert Duggan - Executive Chairman Conference Call Participants Anthony Petrone - Mizuho Securities Robert Lovgren - Medical Hope Production Operator Greetings, and welcome to the Pulse Biosciences First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Pulse Biosciences Inc (PLSE) Q1 2024 Earnings Call Transcript

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the first procedure with the CellFX nsPFA Percutaneous Electrode System in the United States has been completed. The successful case is the first in the Company's pilot program which follows the March 2024 U.S. FDA 510(k) clearance for the ablation of soft tissue in percutaneous and intraoperative.

News for Pulse Biosciences Stock (PLSE)